Get the Stockscreener App
3.14
4.70%
0.16
Skye Bioscience Inc stock is traded at $3.14, with a volume of 143.69K.
It is up +4.70% in the last 24 hours and up +1.63% over the past month.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
See More
Previous Close:
$2.98
Open:
$3.01
24h Volume:
143.69K
Relative Volume:
0.80
Market Cap:
$92.75M
Revenue:
-
Net Income/Loss:
$-21.24M
P/E Ratio:
-3.7475
EPS:
-0.8379
Net Cash Flow:
$-22.47M
1W Performance:
-2.80%
1M Performance:
+1.63%
6M Performance:
-39.53%
1Y Performance:
+0.00%
1-Day Range:
$2.95
$3.20
1-Week Range:
$2.70
$3.55
52-Week Range:
$2.31
$17.65
Skye Bioscience Inc Stock (SKYE) Company Profile
Name
Skye Bioscience Inc
Sector
Industry
Phone
(858) 410-0266
Address
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1978 | 409.20M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.70 | 372.90M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.4356 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.26 | 96.03M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
4.00 | 52.42M | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-09-24 | Initiated | Craig Hallum | Buy |
| May-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-24 | Initiated | Oppenheimer | Outperform |
Skye Bioscience Inc Stock (SKYE) Latest News
Skye Bioscience (NASDAQ:SKYE) Stock Price Up 8.5% – Here’s Why - Defense World
Financial Survey: Cumberland Pharmaceuticals (NASDAQ:CPIX) versus Skye Bioscience (NASDAQ:SKYE) - Defense World
Cantor Fitzgerald maintains $14 target on Skye Bioscience stock By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains $14 target on Skye Bioscience stock - MSN
JPMorgan Chase & Co. Sells 3,609 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
JPMorgan Chase & Co. Has $44,000 Stock Holdings in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience Announces Participation in February Conferences - The Manila Times
Obesity Drug Developer Skye Bioscience Takes Center Stage at Major Healthcare Conferences - StockTitan
Reviewing Achaogen (OTCMKTS:AKAOQ) & Skye Bioscience (NASDAQ:SKYE) - Defense World
(01/30/25) Top Picks 2025: Skye Bioscience (SKYE) - Moneyshow.com
Cantor Fitzgerald Estimates Skye Bioscience FY2025 Earnings - MarketBeat
Cantor Fitzgerald Forecasts Skye Bioscience FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts Skye Bioscience FY2025 Earnings - Defense World
Barclays PLC Has $226,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Barclays PLC Has $226,000 Stock Holdings in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Down 2.5%Should You Sell? - MarketBeat
12,200 Shares in Skye Bioscience, Inc. (NASDAQ:SKYE) Acquired by Jane Street Group LLC - Defense World
Jane Street Group LLC Invests $48,000 in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience targets Q4 for obesity drug data - Investing.com India
Skye Bioscience Provides 2025 Look Ahead and Year in Review - The Manila Times
Skye Bioscience Sets Major 2025 Milestones for Revolutionary Obesity Drug Trial - StockTitan
Financial Analysis: Skye Bioscience (NASDAQ:SKYE) vs. VYNE Therapeutics (NASDAQ:VYNE) - Defense World
Geode Capital Management LLC Purchases 15,614 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Acquired by Geode Capital Management LLC - Defense World
Barclays PLC Increases Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Barclays PLC Buys 15,551 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
State Street Corp Acquires 23,201 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
State Street Corp Increases Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Down 3% – Should You Sell? - Defense World
Skye Bioscience (NASDAQ:SKYE) Shares Down 3% – Should You Sell? - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Down 3%Time to Sell? - MarketBeat
Skye Bioscience to Present at J.P. Morgan Healthcare Conference - GlobeNewswire
Skye Bioscience to Present at J.P. Morgan Healthcare Conference 2025: Spotlight on Obesity Treatment Pipeline - StockTitan
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Bought by BNP Paribas Financial Markets - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Purchased by BNP Paribas Financial Markets - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Sees Significant Drop in Short Interest - MarketBeat
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of “Buy” from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Skye Bioscience's SWOT analysis: nimacimab's potential in obesity stock market - Investing.com
Point72 Asset Management L.P. Has $1.63 Million Stock Holdings in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy (NASDAQ:SKYE) - Seeking Alpha
Skye Bioscience (NASDAQ:SKYE) Shares Down 12.7%Should You Sell? - MarketBeat
Baker BROS. Advisors LP Purchases 934,634 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Baker BROS. Advisors LP Has $5.61 Million Holdings in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Skye Bioscience, Inc. (NASDAQ:SKYE) Short Interest Up 26.8% in November - MarketBeat
Craig-Hallum Initiates Coverage of Skye Bioscience (SKYE) with Buy Recommendation - MSN
Top 10 startups in Ophthalmology in San Diego, United States in Nov, 2024 - Tracxn
Don't Ignore The Insider Selling In Skye Bioscience - Simply Wall St
Skye Bioscience chief development officer sells shares worth $97,721 By Investing.com - Investing.com South Africa
Skye Bioscience chief development officer sells shares worth $97,721 - Investing.com India
Skye Bioscience Inc Stock (SKYE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Skye Bioscience Inc Stock (SKYE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Diep Tuan Tu | Chief Development Officer |
Nov 15 '24 |
Sale |
5.55 |
85 |
472 |
101,748 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 18 '24 |
Sale |
4.99 |
43,206 |
215,598 |
166,342 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 15 '24 |
Sale |
5.55 |
190 |
1,054 |
209,548 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 18 '24 |
Sale |
4.99 |
82,546 |
411,905 |
329,823 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 15 '24 |
Sale |
5.55 |
364 |
2,020 |
412,369 |
| Grayson Paul A. | Director |
Nov 18 '24 |
Sale |
4.99 |
86,244 |
430,358 |
259,701 |
| Grayson Paul A. | Director |
Nov 15 '24 |
Sale |
5.55 |
307 |
1,704 |
345,945 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):